Search
Halozyme Therapeutics Inc
HALOAdd to Watchlist
68.550USD
-0.020-0.03%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
8.12BMarket Cap
23.19P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Halozyme Therapeutics Inc is 7.00, ranking 112 out of 157 in the Pharmaceuticals industry. The average price target is 77.00, with a high of 92.00 and a low of 56.00.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
85.444
Target Price
+24.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Halozyme Therapeutics Inc
HALO
10
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Halozyme Therapeutics Inc's expected revenue for the next quarter?
Halozyme Therapeutics Inc's expected revenue is 403.98M.
What is Halozyme Therapeutics Inc's price target?
Analysts forecast that Halozyme Therapeutics Inc's price target is USD 77.00, with the highest forecast at USD 92.00 and the lowest forecast at USD 56.00.
How have Halozyme Therapeutics IncHALO's recent earnings per share performed?
The market expectation was USD 1.27, while Halozyme Therapeutics IncHALO's earnings per share (EPS) for the previous quarter was USD -1.20. EPS for the next quarter is expected at USD 1.82.
What is the analyst rating for Halozyme Therapeutics Inc?
Based on the ratings of Halozyme Therapeutics Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
